Related Experiment Video
Updated: May 3, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Reversing fibrosis in metabolic dysfunction-associated steatohepatitis-beyond telling patients to lose weight
Leandro Sierra1, Lily Liu2, Akash Khurana3
1Department of Internal Medicine, Cleveland Clinic, Cleveland, OH.
Abstract:
To reverse fibrosis in late-stage metabolic dysfunction-associated steatohepatitis (MASH), guidelines recommend that patients shed at least 10% of their body weight. However, losing this much weight remains a challenge for most patients, especially with lifestyle modifications alone. Moreover, not all patients with MASH are overweight or obese. This review summarizes pharmacologic, surgical, and bariatric endoscopic treatments for MASH to guide primary care physicians and internists.
More Related Videos
Related Concept Videos
Cirrhosis II: Pathophysiology
Chronic Pancreatitis II: Collaborative Care
Assessment:
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Chronic Pancreatitis II: Pathophysiology
Atherosclerosis III: Management
Cirrhosis I: Introduction

